Structure Therapeutics (GPCR) Stock Price, News & Analysis

Company Overview

Structure Therapeutics, Inc. (NASDAQ: GPCR) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel small‐molecule modulators of G protein‐coupled receptors (GPCRs). Founded as a spin‐out from Sosei Heptares in early 2022, the company leverages a proprietary structure‐guided drug design platform to address high‐value therapeutic targets across pain, central nervous system, metabolic and immuno‐inflammatory disorders. Structure Therapeutics seeks to advance orally bioavailable, non‐opioid therapies by combining deep expertise in structural biology, medicinal chemistry and target validation.

The company’s research and development activities center on its proprietary GPCR platform, which integrates high‐resolution crystallography, computational modeling and advanced chemistry libraries. This platform allows Structure Therapeutics to systematically engineer receptor binding, selectivity and signaling profiles, accelerating the progression from target identification to clinical candidate. Its lead program, a selective modulator for chronic pain, is currently in early clinical evaluation and exemplifies the company’s approach to address unmet needs without relying on traditional opioid mechanisms.

Structure Therapeutics operates research facilities in Cambridge, UK, and Cambridge, Massachusetts, reflecting its commitment to maintaining strong discovery operations on both sides of the Atlantic. The company has established strategic partnerships and research collaborations with academic centers and biopharmaceutical organizations to expand its pipeline across multiple therapeutic areas. These alliances enhance its ability to rapidly advance preclinical candidates toward human studies while leveraging external expertise in disease biology and clinical development.

Under the leadership of CEO Robert Icke, a veteran in GPCR drug discovery, Structure Therapeutics is guided by a management team with extensive experience in bringing small‐molecule therapeutics from concept to market. The company’s board and scientific advisory committees feature industry leaders in structural biology, pharmacology and translational medicine. Together, they aim to harness the untapped potential of GPCR targets and deliver innovative therapeutics that improve patient outcomes worldwide.

Key Stats

• Today's Range: $19.83 to $20.81
• 50-Day Range: $20.44 to $27.55
• 52-Week Range: $13.22 to $47.48
• Volume: 372,490 shs
• Average Volume: 835,751 shs
• Market Capitalization: $1.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $76.17
• Consensus Rating: Buy

Structure Therapeutics Stock Analysis - MarketRank™

Structure Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 1276th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Structure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Structure Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Structure Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Structure Therapeutics is -23.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Structure Therapeutics is -23.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Structure Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.12% of the float of Structure Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Structure Therapeutics has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Structure Therapeutics has recently decreased by 9.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Structure Therapeutics does not currently pay a dividend.

Dividend Growth

Structure Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.12% of the float of Structure Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Structure Therapeutics has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Structure Therapeutics has recently decreased by 9.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Structure Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Structure Therapeutics this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for GPCR on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Structure Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.43% of the stock of Structure Therapeutics is held by insiders.

Percentage Held by Institutions

91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GPCR Stock Analysis - Frequently Asked Questions

How have GPCR shares performed this year?

Structure Therapeutics' stock was trading at $27.12 on January 1st, 2025. Since then, GPCR stock has decreased by 24.0% and is now trading at $20.6190.

How were Structure Therapeutics' earnings last quarter?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) released its earnings results on Thursday, May, 8th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.03.

When did Structure Therapeutics IPO?

Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share.

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Structure Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GPCR
• CIK: 1888886
• Web: www.structuretx.com
• Phone: 628-229-9277
• Fax: N/A
• Employees: 136
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $76.17
• High Stock Price Target: $118.00
• Low Stock Price Target: $50.00
• Potential Upside/Downside: +269.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$122.53 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -16.35%
• Return on Assets: -15.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.29
• Quick Ratio: 23.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.10 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 57,343,000
• Free Float: 51,936,000
• Market Cap: $1.18 billion
• Optionable: Optionable
• Beta: -1.87